Dr. Simpson's TRT advice: mostly right, but incomplete

What did @drterrysimpson actually say?

Dr. Simpson's core argument is that testosterone replacement therapy marketing is "irresponsible" because it oversimplifies a genuinely complex clinical workup. He walked through what a real TRT evaluation looks like: two separate fasting morning testosterone draws, localization of the problem (brain versus testes), prostate-specific antigen testing, digital rectal exam, sleep apnea screening, cardiovascular history review, and hematocrit monitoring. He closed by steering viewers toward a board-certified endocrinologist rather than a DTC telehealth product.

The video is refreshingly specific for TikTok. He is not vague about what "proper workup" means. He names the tests, he names the risks, and he names the anatomical distinction between primary and secondary hypogonadism. That specificity is worth acknowledging before we get into where he left gaps.

Does the science back this up?

Mostly yes, and the guidelines agree with him. The two-morning-draw requirement is well-established, and the localization step he describes maps directly onto clinical practice.

The Endocrine Society's 2018 clinical practice guideline (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommends confirming low testosterone with at least two early-morning measurements before initiating therapy. The guideline also recommends against TRT in men with untreated obstructive sleep apnea, recent cardiovascular events, or elevated hematocrit, which tracks exactly with what Dr. Simpson listed. The PSA and digital rectal exam recommendations align with the guideline's screening requirements for men at higher prostate cancer risk. The localization workup, specifically distinguishing primary hypogonadism (testicular failure) from secondary hypogonadism (hypothalamic-pituitary dysfunction), matters because secondary causes can sometimes be treated without exogenous testosterone at all, a point Dr. Simpson implied but did not fully explain to his audience.

What did they get right or wrong?

He got the framework right. The clinical logic he presented is accurate and reflects what major endocrinology bodies actually recommend. The critique of direct-to-consumer TRT marketing is legitimate: studies have documented that many online TRT services skip the two-draw confirmation and do not systematically screen for sleep apnea or elevated hematocrit (Jasuja et al., 2017, JAMA Internal Medicine).

Where he left money on the table: he said "see a board-certified endocrinologist" without acknowledging that urologists and internists with appropriate training also manage hypogonadism competently per guideline recommendations. Restricting the advice to endocrinologists only could leave men in areas with limited specialist access without a clear path forward. He also described wanting to check that patients "don't have a recent heart attack or heart attack," which is clearly a verbal slip in delivery, not a clinical error. The cardiovascular contraindication he was gesturing at is real and supported by guideline language around recent major adverse cardiac events.

What should you actually know?

If you think you have low testosterone, the bar for diagnosis is higher than a single blood test ordered through an app. Two fasting morning draws are the floor, not the ceiling. Testosterone levels fluctuate with sleep, illness, stress, and time of day, which is exactly why the two-draw requirement exists.

The localization step Dr. Simpson mentioned matters more than most social media content acknowledges. Secondary hypogonadism, where the problem is upstream in the pituitary or hypothalamus, can have treatable underlying causes including hyperprolactinemia, hemochromatosis, or pituitary adenoma. Starting exogenous testosterone without ruling those out means potentially missing a diagnosis. A 2020 analysis in Endocrine Reviews (Millar et al.) found that secondary hypogonadism is underdiagnosed partly because the workup is skipped in favor of faster symptom-based prescribing. Dr. Simpson is right to flag this, even if he only mentioned it briefly.

One practical note: hematocrit elevation is not a minor side effect. Testosterone therapy increases red blood cell mass, and polycythemia raises stroke and clotting risk. The monitoring schedule he referenced, rechecking labs several months after initiation, is consistent with the Endocrine Society's 3-to-6 month follow-up recommendation.